At a glance
- These clinical considerations provide guidance for healthcare professionals and public health officials concerning the use of COVID-19 vaccines in the United States for the 2026-2027 season. The recommendations in this document reflect CDC’s adult and pediatric immunization schedule as of July 2025.
- The Table of Contents on each page can be used to navigate to all guidance pages.
Summary of recent changes
Last updated September 23, 2025
- A 2026-2027 COVID-19 vaccine is recommended for all adults ages 18 years and older in the United States for the prevention of COVID-19.
- A 2026-2027 COVID-19 vaccine is also recommended for all children ages 6 months–17 years with moderate to severe immunocompromise; for all other children, a COVID-19 vaccine is recommended through shared clinical decision-making.
Where a recommendation on this page describes use that is not within the FDA-approved indication, the page identifies it as off-label.
- Pfizer-BioNTech COVID-19 Vaccine is no longer authorized for children ages 6 months–4 years. The only FDA-approved COVID-19 vaccine available for this age group is Moderna (Spikevax).
Content Source
National Center for Immunization and Respiratory Diseases; Coronavirus and Other Respiratory Viruses Division
About This Page
Published: May 1, 2025
Updated: September 23, 2026
This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.
Reviewed: September 23, 2026
The information on this page was last reviewed by subject matter experts to ensure accuracy.